^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HFB200603

    i
    Other names: HFB200603, HFB 2006, HFB2006
    Associations

    News

    Trials
    Company:
    HiFiBiO
    Drug class:
    BTLA inhibitor
    Related drugs:
    Associations

    News

    Trials
    14d
    HFB-200603-01: A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=83, Active, not recruiting, HiFiBiO Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    Tevimbra (tislelizumab-jsgr) • HFB200603
    2years
    A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=83, Recruiting, HiFiBiO Therapeutics | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    Tevimbra (tislelizumab-jsgr) • HFB200603
    over2years
    A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=83, Recruiting, HiFiBiO Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    Tevimbra (tislelizumab-jsgr) • HFB200603
    over2years
    A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=83, Not yet recruiting, HiFiBiO Therapeutics
    New P1 trial • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    Tevimbra (tislelizumab-jsgr) • HFB200603